Noticias

Noticias

  • Título: Cook Medical Makes Zilver® PTX® Drug-Eluting Stent Available in Canada
  • Fecha: 05-06-2014

  • Bloomington,Ind. — CookMedical launched its Zilver® PTX® Drug-Eluting Peripheral Stent in Canada atthe Canadian Interventional Radiology Association (CIRA) meeting in Montreal, Canada. It’s the first drug-coated stent in Canada indicated to treatperipheral arterial disease (PAD) in the superficial femoral artery (SFA).

    “Launching Zilver PTX in Canada brings the benefits ofdrug-eluting stents to Canadian PAD patients,” said Mark Breedlove, vicepresident of Cook Medical’s Peripheral Intervention clinical division. “We’revery pleased to be the company that introduces this technology in Canada.”

    The device is a self-expanding metal stent coated withthe drug paclitaxel. The drug is absorbed by the surrounding tissues to preventthe growth of scar tissue that can reclog the artery. It is indicated for usein treating new or recurring lesions as long as 140 mm per leg. In Canada,Zilver PTX is sold in 40, 60, 80 and 100 mm lengths and in 6 and 7 mmdiameters.

    Four-year data from the internationalZilver PTX randomized trial show 75.0 percent of patients treated with ZilverPTX maintained blood flow in the SFA at four years.[1] That compares to 57.9 percent patency[2] for patients who received a bare-metal Zilver stent.

    Since its initial launch in 2009 inEurope, Zilver PTX has been used to treat more than 25,000 PAD patients. Thedevice is now available in more than 50 countries across Europe, the MiddleEast, North and South America, and the Asia-Pacific region. For moreinformation, go to Zilver PTX.



  • Fuente: endovascular.es